Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia

Thomas J. Hwang; Aaron S. Kesselheim; Ariadna Tibau; ChangWon C. Lee; Kerstin N. Vokinger

Journal ArticleOPEN ACCESS

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia

Hwang T
Kesselheim A
Tibau A
et al.

JCO Oncology Practice (2022) 18(9) e1522-e1532

DOI: 10.1200/op.21.00909

19Citations

18Readers

Abstract

PURPOSE:Regulatory agencies have sought to speed up the review of new cancer medicines and reduce delays in approval between countries. We examined trends in regulatory review times and association...

Cite

CITATION STYLE

APA

Hwang, T. J., Kesselheim, A. S., Tibau, A., Lee, C. C., & Vokinger, K. N. (2022). Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice, 18(9), e1522–e1532. https://doi.org/10.1200/op.21.00909

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia

Abstract

Cite

Register to see more suggestions